The role of low molecular weight heparin to prevent miscarriage in thrombophilic women

Pierpaolo Di Micco; Maristella D’Uva

doi:10.1160/TH05-10-0652

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(05): 897-898
DOI: 10.1160/TH05-10-0652

Editorial Focus

Schattauer GmbH

The role of low molecular weight heparin to prevent miscarriage in thrombophilic women

Authors

Pierpaolo Di Micco

¹Divisione di Medicina Interna, Fatebenefratelli Hospital of Naples, Naples, Italy
Maristella D’Uva

²Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Area Funzionale di Medicina della Riproduzione ed Endoscopia Ginecologica, Università degli Studi di Napoli Federico II, Naples, Italy

Abstract

Full Text

References

References
1 DiMicco P, D’Uva M, Strina I. et al. The role of D-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia-induced sterility. J Transl Med 2004; 2: 38.
2 Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1994; 82: 634-40.
3 Brenner B, Sarig G, Weiner Z. et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
4 Sanson BJ, Fierich PW, Simioni P. et al. The risk of abortion and stillbirth in antithrombin-, protein C, and protein S deficient women. Thromb Haemost 1996; 75: 387-8.
5 Grandone E, Margaglione M, Colaizzo D. et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-4.
6 Pihusch R, Buchholz T, Lohse P. et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-31.
7 Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W. et al. Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost 2004; 91: 694-9.
8 Cervera R, Balash J. The management of pregnant patients with antiphospholipid syndrome. Lupus 2004; 13: 683-7.
9 Azem F, Many F, Yovel I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19: 368-70.
10 Grandone E, Colaizzo D, Lo Bue A. et al. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001; 76: 201-2.
11 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
12 Greer I. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Clin Obstet Gynaecol 1997; 11: 403-30.
13 Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-11.
14 Brenner B, Hoffman R, Blumenfeld Z. et al. Gestational outcome in thrombofilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
15 Sarig G, Blumenfeld Z, Leiba R. et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005; 94: 980-5.
16 Brenner B, Hoffman R, Carp H. et al. for the LIVEENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3: 227-9.